Lonza and Antharis Therapeutics, Inc., a biopharmaceutical company developing next-generation antibody-based therapeutics for oncology, today announced an exclusive, target-specific licensing agreement to develop novel dual-payload ADCs targeting gastrointestinal (GI) cancers.